According to a December 17 article in the Financial Times, some of China’s 2019 coronavirus (CCP) vaccines have entered human clinical trials without even releasing data from the first phase of animal testing.
The article, entitled “Problems to be solved when Chinese vaccines go global,” was written by Cao Xin, who is from the South China Press Group and is currently secretary-general of the International Public Opinion Research Center of the Chahar Society, and pointed out that the first problem facing Chinese vaccines going abroad is the procedure of vaccine quality qualification. According to the article, according to the internationally accepted procedure for developing vaccines, new vaccines should undergo clinical tests on animals and humans and be proven to be qualified before they can be used in humans. The first step is to conduct experiments with animals and release the test data and information to the public before entering the phase 3 human clinical trials.
The article quoted Chinese Vice Premier Sun Chunlan as having said during a recent visit to relevant units in Beijing that at this stage of China’s vaccine development process, it is important to continue to promote Phase 3 clinical trials scientifically and rigorously, and to do a good job in reviewing and approving the vaccine “in strict accordance with laws, regulations and internationally recognized technical standards” to ensure that the vaccine is safe and effective and can stand up to all tests. To ensure that the vaccine is safe and effective and can withstand the test from all sides. According to the article, Sun Chunlan’s above-mentioned talk shows that Chinese vaccines have not gone through the entire internationally recognized R&D process, which is different from the vaccine R&D situation in Europe and the US.
According to the author, Cao Xin, quoted by the Financial Times, to his knowledge, none of the current Chinese vaccines have been approved by the State Drug Administration. In other words, these vaccines are legally problematic. In contrast, the vaccines that are currently in use in the U.K. and the U.S. have legal approvals.
As for the United Arab Emirates instead approving the Chinese vaccine for use first a few days ago, the article points out that this may seem legal, but if health-threatening problems arise in the future, given China’s sensitive international environment, registration abroad does not get rid of diplomatic, political, legal and economic responsibilities. According to the article, if problems arise with Chinese vaccines, the world will have a very negative impression of China’s technological level, product quality and overall national power. In international public opinion, a wave of media reports focused on criticism of China would be unleashed, and the fact that even North Korea is considering the use of Russian rather than Chinese vaccines would provide a basis for international criticism and create a diplomatic and political controversy. In China’s sensitive international environment, too, the possibility of economic disputes and lawsuits between individuals, groups, and even countries is high if there is a problem with the vaccine, which would make things even more complicated.
Recent Comments